Result card
|
English
No adaptation help available for this domain
|
Authors: Mirjana Huic, Eleftheria Karampli, Silvia Florescu, Cristian Vladescu
Internal reviewers: Antonio Migliore, Pernilla Östlund, Frida Mowafi, Daniela d’Angela, Jesus Gonzalez
Apart of health professionals (primary care physicians and nurses, laboratory staff), people invited to screening will use this technology.
The EU guidelines for quality assurance in CRC screening and diagnosis {6} state that “people invited to screening need specific and clear instructions on how to use the kit. Factors that enhance accessibility and uptake are the design of a test kit, and simple and clear instructions which should be provided with the test kit. Effective sample collection is critical to the success of a screening programme with FOBT, so the process of collection should be as simple as possible. Physical and mental disabilities in the screened age group could be one of the reasons for non-participation.
Laboratory staff is necessary in settings where a screening programme is based on a FOBT. The training and skills required are dependent on the type of the test (gFOBT or iFOBT, qualitative or quantitative); staffs require supervision by appropriately qualified individual with expertise in clinical biochemistry, and the day-to-day running of the laboratory must be managed by an appropriate skilled scientific officer. Laboratory staff required training in good laboratory practice, training in the performance of the FOBT, and training in the use of the IT system used to record results, in addition to basic understanding of the CRC process. Laboratory Manager required training on managerial skills, internal quality control and external quality assurance; interactions between the laboratory process and the whole screening programme. Individual with expertise in clinical biochemistry which is responsible for the operation of laboratory required training on in-depth understanding of CRC, screening process, performance characteristics of different type of FOBT; in-depth understanding of the technology required to perform the FOBT.
Primary care physicians and nurses in primary care should be informed about national CRC screening programme, to be able to help people invited to screening, if they asked for, in form of answering questions on screening and tests, but not to perform FOBT on an individual basis”.
1. Young GP, St John DJ, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. The American journal of gastroenterology. 2002;97(10):2499-507. eng.
13. Exact Sciences Corp. Top-Line Data Show Exact Sciences' Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal Cancer. [Internet]. 2013, April 18 [cited 2013 Aug 9]. Available from: http://investor.exactsciences.com/releasedetail.cfm?ReleaseID=757341.
14. ClinicalTrials.gov. Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C) [Internet]. U.S. National Institutes of Health; 2013, Jun 18 [cited 2013 Aug 9]. Available from: http://prsinfo.clinicaltrial.gov/ct2/show/record/NCT01397747?id=NCT01397747&rank=1).
17. Epigenomics AG. Epigenomics AG submits the fourth module and completes its PMA submission to the FDA for Epi proColon®. [Internet]. Epigenomics AG,; 2013, Jan 7 [cited 2013 Oct 26]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01580540.
18. ClinicalTrials.gov. Head to Head Study Epi proColon and FIT. [Internet]. U.S. National Institutes of Health; 2013 [updated 2013, Feb 6; cited 2013 Oct 26]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01580540.
19. Epigenomics AG. Results of Comparative Study between Epigenomics Epi proColon® and FIT to be Presented at Digestive Disease Week. [Internet]. Epigenomics AG,; 2013, Mar 15 [updated 2011; cited 2013 Oct 26]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01580540.